SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a...
Cerexa expands portfolio of novel anti-infective therapies through in-licensing agreement with Meiji Seika Kaisha
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.